Revance Therapeutics Investors Urged to Act Before March 2025 Deadline

Glancy Prongay & Murray LLP is reminding investors of the approaching March 4, 2025 deadline to file a lead plaintiff motion in a class action lawsuit. This action is on behalf of investors who bought or acquired shares of Revance Therapeutics, Inc. (“Revance” or the “Company”) RVNC securities during the period from February 29, 2024, to December 6, 2024 (the “Class Period”).

IF YOU SUFFERED A LOSS ON YOUR REVANCE INVESTMENTS, CLICK HERE TO LEARN ABOUT YOUR OPTIONS TO RECOVER UNDER FEDERAL SECURITIES LAWS.

What Occurred?

On September 23, 2024, Revance informed the U.S. Securities and Exchange Commission that it had “received a notice to remedy alleged material breaches.” These included issues with the maximum levels of buffer stock and focused efforts promoting and selling Teoxane products. Consequently, a previously announced tender offer by Crown Laboratories, Inc. (“Crown”) was postponed until at least October 4, 2024.

Following this revelation, Revance’s stock price dropped $0.44, or 7.7%, closing at $5.37 per share on September 23, 2024, negatively impacting investors.

Then, on December 9, 2024, Revance announced it had amended its merger agreement with Crown, now offering to buy all outstanding shares of Revance’s common stock for just $3.10 per share—down more than 50% from the original offer.

This news led to Revance’s stock plummeting an additional $0.79, or 20.7%, to close at $3.03 per share on December 9, 2024, resulting in more losses for investors.

The Lawsuit’s Allegations

The complaint states that during the Class Period, the Defendants made significantly misleading statements and failed to reveal important adverse facts regarding Revance’s business and future. Specifically, it argues that Defendants did not disclose: (1) Revance’s material breaches of the Distribution Agreement; (2) the risks of litigation, financial loss, and reputational damage for the Company; (3) concerns over potential delays or amendments to the Tender Offer; and (4) that the Defendants’ optimistic claims lacked a reasonable foundation.

If you purchased or acquired Revance securities during the Class Period, you may seek appointment as lead plaintiff in this class action lawsuit by moving the Court no later than March 4, 2025.

Contact Information for Participation or Inquiry:

If you want to know more about this case or have questions about your rights, please reach out to:

Charles Linehan, Esq.,

Glancy Prongay & Murray LLP,

1925 Century Park East, Suite 2100,

Los Angeles, California 90067

Email: shareholders@glancylaw.com

Telephone: 310-201-9150,

Toll-Free: 888-773-9224

Visit us at www.glancylaw.com.

You can also find updates on LinkedIn, Twitter, or Facebook.

If you email us, please include your address, phone number, and how many shares you purchased.

You do not need to take any action at this point to be a member of the class action; you can choose to hire your own lawyer or remain uninvolved. This press release might be considered Attorney Advertising in some locations according to local laws and ethical guidelines.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250110892194/en/

Contact Us:

Glancy Prongay & Murray LLP,

1925 Century Park East, Suite 2100

Los Angeles, CA 90067

Charles Linehan

Email: shareholders@glancylaw.com

Telephone: 310-201-9150

Toll-Free: 888-773-9224

Visit our website at: www.glancylaw.com.